Peramivir + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute, Uncomplicated Human Influenza
Conditions
Acute, Uncomplicated Human Influenza
Trial Timeline
Jul 1, 2008 → Oct 1, 2009
NCT ID
NCT00705406About Peramivir + Placebo
Peramivir + Placebo is a phase 2 stage product being developed by BioCryst Pharmaceuticals for Acute, Uncomplicated Human Influenza. The current trial status is completed. This product is registered under clinical trial identifier NCT00705406. Target conditions include Acute, Uncomplicated Human Influenza.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00705406 | Phase 2 | Completed |
| NCT00610935 | Phase 3 | Terminated |
Competing Products
20 competing products in Acute, Uncomplicated Human Influenza